

DEEP DIVE INTENSIVE

CME Dinner Symposium

Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk

Thursday, October 22, 2015, 7:00 – 9:00pm, Sheraton Boston

*Supported by educational grants from Genzyme, a Sanofi company, sanofi-aventis U.S.,
and Regeneron Pharmaceuticals*

Symposium Overview

During this comprehensive learning experience, expert faculty will examine current lipid guidelines, the unmet need and residual risk of poorly controlled LDL-C, and exciting genetic insights that have expanded treatment targets. Attendees will leave with the latest information on novel LDL lowering therapies, including PCSK9 inhibitors. Clinical case examples will provide tactics for treatment intensification and how best to integrate new therapies into management plans for high-risk patients.

Learning Objectives

Upon completion of these educational activities, participants will be better able to:

- Determine optimal LDL-C target goals in high-risk individuals, including those with residual ASCVD risk such as familial hypercholesterolemia, diabetic dyslipidemia and/or statin intolerance in light of current consensus recommendations.
- Assess the genetic basis and mechanistic rationale for lowering LDL-C through novel pathways, and the importance of LDL receptor recycling in cholesterol homeostasis.
- Review the latest clinical trial data and physiologic rationale for the new drug classes, practicalities of their administration, including potential for use as replacement or complementary treatment for patients on a statin, patient selection for use of these drugs, as well as the need for additional outcomes studies.
- Discuss the application of novel LDL lowering therapies, including PCSK9 inhibitors, to address residual ASCVD risk in a range of patient groups, including those with primary or familial hypercholesterolemia.



Agenda & Faculty

Welcome and Introductions

Chairperson: **Christie M. Ballantyne, MD**

LDL-C Focused Cardioprotection: What Do Recent Trials and Global Lipid Guidelines Tell Us?

Presenter: **Christie M. Ballantyne, MD**

Genetic and Mechanistic Insights into Novel Targets and Treatment Advances for LDL Lowering

Presenter: **Jay D. Horton, MD**

Clinical Evidence for New Therapeutic Options: Focus on PCSK9 Inhibitors

Presenter: **Jennifer G. Robinson, MD, MPH**

Special Considerations in Familial Hypercholesterolemia

Presenter: **Patrick Moriarty, MD**

Evidence to Practice Expert Roundtable: Managing the Spectrum of High-Risk Patients with Hypercholesterolemia and Increased ASCVD Risk with Audience Q&A

Moderator: **Christie M. Ballantyne, MD**

Discussants: **All**

Note: Agenda and Faculty subject to change.